Bacillus subtilis for producing human lactoferrin and use thereof

By screening suitable promoters and expression vectors, combining RBS and signal peptides, Bacillus subtilis, which efficiently expresses human lactoferrin, solved the expression difficulties and secretion problems of human lactoferrin in the bacterial system, and achieved the goal of achieving the Efficient and economical production.

WO2024230181A1PCT designated stage expired Publication Date: 2024-11-14JIANGNAN UNIV +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/140638
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2023-12-21
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

The prior art is difficult to efficiently produce human lactoferrin on a large scale, and it is difficult to express and costly in the bacterial expression system. Bacillus subtilis is difficult to secrete proteins ≥80kDa, affecting growth.

Method used

By screening suitable promoters and expression vectors, combining ribosome binding sites (RBS) and signal peptides, Bacillus subtilis strains that efficiently express human lactoferrin were constructed, and suitable RBS-signal peptide combinations were screened using the SCORES method. , fuse 6×His tags for secretion and purification, reducing production costs.

Benefits of technology

It has achieved efficient expression and secretion of human lactoferrin, simplified the subsequent separation and purification process, reduced production costs, and has broad application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023140638_14112024_PF_FP_ABST
    Figure CN2023140638_14112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided are a bacillus subtilis for producing human lactoferrin and the use thereof, which belongs to the field of biotechnology. First, a recombinant fiB.subtilis strain HLF1 capable of efficiently expressing HLF is successfully constructed by screening appropriate promoters and expression vectors, wherein the overall yield thereof is 18.91 ng / L. Second, a signal peptide-RBS combination suitable for the secretion and expression of HLF is screened by means of a SCORE method, and further secretion and expression of HLF is successfully achieved, wherein the recombinant plasmids with the highest secretion amount are pHT-P21-RBSl-SPYycP-HLF and pHT-P21-RBS2-SPYncM-HLF, which have the total production amount of HLF protein of 39.1 ng / L and 41.2 ng / L, respectively; and have the amount of secreted protein of 16.9 ng / L and 17.4 ng / L, respectively. The humanized HLF produced by the constructed recombinant bacterium has a stable expression, a high expression amount and a wide application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Bacillus subtilis for producing human lactoferrin and application thereof Technical Field

[0001] The invention relates to Bacillus subtilis for producing human lactoferrin and application thereof, belonging to the field of biotechnology. Background Art

[0002] Lactoferrin (LF) is a multifunctional globular glycoprotein that belongs to the transferrin family, hence its also known as lactotransferrin (LTF). Its molecular weight ranges from 76 to 80 kDa and is widely present in various secretions, such as milk, saliva, tears, and nasal mucus. Lactoferrin is also present in mid-stage neutrophils and is secreted by some acinar cells. The concentration of lactoferrin is highest in human colostrum, followed by human breast milk, with the lowest concentration in milk (150 mg / L). Lactoferrin is a component of the human immune system. It has antimicrobial activity (antibacterial and antifungal), is part of the innate defense, and is primarily found in the mucous membranes. Lactoferrin protects infants from pathogens such as bacteria. Lactoferrin also interacts with DNA and RNA, polysaccharides, and heparin, and exhibits some biological functions in complex with these ligands.

[0003] Currently, lactoferrin is primarily obtained from fresh cow's milk. However, only 1g of lactoferrin can be extracted from 14kg of milk, which is expensive. Furthermore, since LF is sensitive to denaturation caused by temperature and other physical and chemical stresses, the extraction process may denature or inactivate the protein. Therefore, the extraction process is very demanding, and large-scale commercialization of HLF using fresh cow's milk extraction is difficult. As a key ingredient in high-end infant formula, lactoferrin remains expensive, reaching as high as 30,000 yuan per kilogram. Therefore, efficient synthesis and large-scale production of lactoferrin have become a pressing challenge in my country. Microbial fermentation can be used to produce HLF on a large scale, reducing production costs. However, as a foreign protein of eukaryotic origin, human HLF faces difficulties in expression, low expression levels, and secretion in bacterial protein expression systems. Therefore, the heterologous expression of LF through genetic engineering combined with molecular biology methods is of great significance, and the construction of a cell chassis capable of efficiently expressing lactoferrin is of great significance.

[0004] Literature reports indicate that lactoferrin can be recombinantly expressed in plant, animal, and microbial cell systems. However, most studies focus on enhancing lactoferrin's antibacterial and other activities through modification and truncation, with few studies targeting the production of food-safe lactoferrin (LF). Bacillus subtilis is a recognized food-safe microorganism (GRAS) and possesses a strong protein secretion capacity. Therefore, it has been used as an expression host for secretory expression of human lactoferrin (HLF). However, HLF is eukaryotic and has antibacterial properties, and the strain's inherent protective mechanisms often cause mutations in the expression vector, resulting in failure to construct the expression vector. Furthermore, literature reports indicate that Bacillus subtilis has difficulty secreting proteins with a molecular weight ≥80 kDa, and excessive intracellular HLF production can significantly impact its growth, making heterologous expression of HLF in Bacillus subtilis relatively challenging.

[0005] Summary of the Invention

[0006] To solve the above problems, the present invention successfully constructed a Bacillus subtilis strain that efficiently expresses HLF by screening suitable promoters and expression vectors, and further increased the expression level of HLF by combining a ribosome binding site (RBS) with a signal peptide. This not only prevents the protein from accumulating in cells but also simplifies the subsequent separation and purification process, thereby reducing the cost of the production process and is expected to be used for subsequent large-scale fermentation production.

[0007] The first object of the present invention is to provide a Bacillus subtilis for producing human lactoferrin, wherein the Bacillus subtilis uses B. subtilis G601 as a starting strain and pHT-01 as an expression vector to heterologously express human lactoferrin regulated by a P21 promoter.

[0008] Furthermore, the B. subtilis G601 uses B. subtilis 168 as the starting strain, integrates the expression transcription factor comK-comS gene in the genome, reverses the mutation of the trpC gene and the gudB gene, and knocks out the extracellular protease serine protease gene aprE, the neutral protease gene nprE, the bacitracin gene bpr, the metalloprotease gene mpr and the neutral protease gene nprB.

[0009] Furthermore, the Bacillus subtilis also includes the use of RBS sequence and signal peptide to regulate the expression of human lactoferrin, wherein the nucleotide sequence of the RBS sequence is as shown in SEQ ID NO.10 or SEQ ID NO.11, and the signal peptide is selected from YycP or YncM. The present invention obtains an HLF expression library with different fluorescence intensities by the SCORES method, and its fluorescence intensity is between 150-500. Single colonies were selected for sequencing according to the fluorescence intensity, and their RBS-signal peptide sequences were obtained, indicating the stability of the connection of the SCORES method. From them, two signal peptides with stronger secretion intensity were selected and combined with RBS, pHT-P21-RBS-SP-HLF-sfGFP was removed by PCR to remove the coding sequence of sfGFP, and the secretory expression plasmid obtained was pHT-P21-RBS1-SP YycP -HLF and pHT-P21-RBS2-SP YncM -HLF.

[0010] Furthermore, the nucleotide sequence of the human lactoferrin is shown in SEQ ID NO.1.

[0011] Furthermore, the amino acid sequence of the human lactoferrin is shown in SEQ ID NO.2.

[0012] Furthermore, the nucleotide sequence of the promoter P21 is shown in SEQ ID NO.3.

[0013] Furthermore, the nucleotide sequence of the signal peptide YycP is shown in SEQ ID NO.6, and the amino acid sequence is shown in SEQ ID NO.8.

[0014] Furthermore, the nucleotide sequence of the signal peptide YncM is shown in SEQ ID NO.7, and the amino acid sequence is shown in SEQ ID NO.9.

[0015] Furthermore, the expression vector pHT-01 is also connected to a purification tag.

[0016] Furthermore, the purification tag is a 6×His tag, whose nucleotide sequence and amino acid sequence are shown in SEQ ID NO.4 and SEQ ID NO.5 respectively. The recombinant protein can be purified using a nickel column through this tag.

[0017] Furthermore, specifically, the introduced recombinant plasmid is obtained by connecting the promoter P21 and the synthetic HLF expression cassette to the commercial plasmid pHT-01. The HLF expression cassette consists of two parts: the HLF gene sequence and the 6×His tag.

[0018] Furthermore, the transcription factor comK-comS gene is expressed via a xylose-inducible promoter P xylA Control expression.

[0019] Furthermore, the transcription factor comK-comS gene is composed of a comK gene whose nucleotide sequence is shown in SEQ ID NO.12 and a comS gene whose nucleotide sequence is shown in SEQ ID NO.13.

[0020] Furthermore, the integration site of the transcription factor comK-comS gene is the extracellular protease gene epr.

[0021] Furthermore, the reverted trpC gene is a gene that mutates the tryptophan-deficient gene trpC2 in B. subtilis 168 into a wild-type gene trpC0 having a nucleotide sequence as shown in SEQ ID NO.14.

[0022] Furthermore, the reversion mutation gudB gene is to mutate the inactive gene gudB in B. subtilis 168 into an active gene gudB having a nucleotide sequence as shown in SEQ ID NO.15. + .

[0023] Furthermore, the Bacillus subtilis is to connect the expression frame or knockout frame of the gene to be edited and the genomic homologous fragment to the pcrF19NM2 vector, and perform gene editing through the CRISPR / Cpf1-based genome scarless editing system.

[0024] The second object of the present invention is to provide the use of the above-mentioned Bacillus subtilis for producing human lactoferrin in the production of lactoferrin.

[0025] The third object of the present invention is to provide a method for producing human lactoferrin, which uses the above-mentioned Bacillus subtilis for fermentation production.

[0026] Furthermore, after activating Bacillus subtilis, the Bacillus subtilis is cultured in a seed culture medium to obtain a seed liquid, and then the seed liquid is inoculated into a fermentation culture medium for fermentation culture to prepare human lactoferrin.

[0027] Furthermore, the seed culture medium is LB culture medium.

[0028] Furthermore, the LB culture medium includes the following components: 5-15 g / L peptone, 1-10 g / L yeast powder, and 5-15 g / L NaCl.

[0029] Furthermore, the fermentation medium is TB medium.

[0030] Furthermore, the fermentation medium contains the following components: 5-20 g / L peptone, 20-30 g / L yeast powder, 5-15 g / L NaCl, 1-10 mL / L glycerol, 1-5 g / L KH2PO4, and 10-20 g / L K2HPO4.

[0031] Furthermore, the Bacillus subtilis is activated in a seed culture medium at 35-37° C. (200-220 rpm, culture for 10-15 h) to obtain a seed solution, which is then inoculated into a fermentation medium at an inoculum rate of 2-5%.

[0032] Furthermore, the Bacillus subtilis seed liquid is cultured in a fermentation medium at 35-37° C. and 200-220 rpm for 14-96 hours.

[0033] Beneficial effects of the present invention:

[0034] The present invention first constructed a recombinant B. subtilis strain HLF1 that can successfully and efficiently express human HLF. The total fermentation yield using it was 18.91 μg / L. In this strain, protein expression was enhanced by the strong promoter P21, and a 6×His tag was fused to the C-terminus of the protein, which can be used for subsequent separation and purification. Secondly, the signal peptide-RBS combination suitable for HLF secretory expression was screened using the SCORE method, successfully achieving secretory expression of HLF. The recombinant plasmid with the highest secretion rate was pHT-P21-RBS1-SP YycP -HLF and pHT-P21-RBS2-SP YncM -HLF, the total HLF protein production was 39.1μg / L and 41.2μg / L, and the secreted protein was 16.9μg / L and 17.4μg / L, respectively. The human HLF produced by the recombinant bacteria constructed in the present invention has stable expression and high expression level, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 is a Western Blot verification graph, M: Marker, 1: empty control, 2: G601-pHT-P43-HLF, 3: G601-pHT-P21-HLF, 4: G601-pP43NMK-HLF;

[0036] Figure 2 is a schematic diagram of the construction of a recombinant expression plasmid;

[0037] Figure 3 is a Western Blot verification graph, M: Marker, 1: 12h fermentation broth sample, 2: 24h fermentation broth sample, 3: 36h fermentation broth sample, 4: 48h fermentation broth sample, 5: empty control;

[0038] Figure 4 is a lactoferrin ELISA standard curve;

[0039] FIG5 is a graph showing the lactoferrin production results. DETAILED DESCRIPTION

[0040] The present invention will be further described below with reference to the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it. However, the embodiments are not intended to limit the present invention.

[0041] The method of the present invention is as follows:

[0042] The present invention uses a high-throughput method called "systemic combinatorial optimization of ribosome binding site (RBS) equipped with signal peptide" (SCORES) to screen RBS-signal peptide combinations suitable for HLF secretory expression. The principle is to fuse the superfolder green fluorescent protein (sfGFP) to the HLF protein, and the fluorescence intensity in the fermentation supernatant is used to characterize HLF secretion. Before linking the RBS library and signal peptide library to the fusion protein via Golden Gate, the screened signal peptide library consists of 173 signal peptides from the endogenous Sec secretion pathway of Bacillus subtilis and a library of 16 RBSs with varying translational strengths, totaling 173 x 16 = 2768 combinations. The specific construction method, primer design, verification primer design and operation process of this series of plasmids are described by Li et al. in A genetic toolkit for efficient production of secretory protein in Bacillus subtilis. Bioresource Technology, 2022.

[0043] The materials involved in the present invention are as follows:

[0044] (1) Strains and vectors

[0045] Plasmid construction was performed in E. coli DH5α and transformed into B. subtilis G601 for HLF expression and fermentation. The vector pHT-01 used was a commercial plasmid.

[0046] (2) Culture medium

[0047] B. subtilis seeds and E. coli were cultured in LB medium (containing 10 g tryptone, 5 g yeast extract, and 10 g NaCl per liter). Fermentation of the engineered strain was performed in TB medium (containing 12 g tryptone, 24 g yeast extract, 10 g NaCl, 2.31 g KH2PO4, 12.54 g K2HPO4, and 4 mL glycerol per liter).

[0048] (3) Starting strain

[0049] B. subtilis G601 was used as the starting strain for HLF expression. This strain is described in Chinese patent CN113957028A. The construction process is as follows:

[0050] (1) The transcription factor comK-comS gene (the nucleotide sequence of comK is shown in SEQ ID NO. 12; the nucleotide sequence of comS is shown in SEQ ID NO. 13) controlled by the xylose-inducible promoter PxylA was integrated into the B. subtilis 168 genome, which greatly improved its transformation efficiency.

[0051] (2) The trpC gene was reversed and the tryptophan-deficient gene trpC2 of B. subtilis 168 was replaced with the wild-type trpC0 (the nucleotide sequence of trpC0 is shown in SEQ ID NO. 14), so that the strain no longer has tryptophan deficiency.

[0052] (3) Reverse mutation of the gudB gene, replacing the inactive gudB with the repeat sequence with the active gudB + (gudB + The nucleotide sequence of which is shown in SEQ ID NO.15), so that it can effectively utilize glutamate family amino acids;

[0053] (4) Using the CRISPR / Cpf1-based Bacillus subtilis multi-gene editing system, the gene knockout frame to be edited and the genomic homologous fragment were connected to the pcrF19NM2 vector, and gene editing was performed using the CRISPR / Cpf1-based genome scarless editing system to knock out six extracellular protease genes (aprE, nprE, bpr, mpr, nprB, epr), and finally the genetically engineered bacteria B. subtilis G601 was obtained.

[0054] Example 1 Construction of HLF recombinant expression plasmid pHT-P21-HLF

[0055] Promoter screening

[0056] To investigate the effect of promoter strength on protein expression, we used different promoters, P43, Pveg, Phag, and P21, to express HLF. During the construction of expression vectors for Pveg and Phag, the HLF expression cassette exhibited fragment deletions or base mutations, leading to premature termination of the open reading frame. Only the P21 and P43 promoter expression vectors were successfully constructed. These vectors were fermented and yields were determined by Western blot. The results, shown in lanes 2 and 3 of Figure 1, show that protein expression from the P21 promoter was higher than that from the P43 promoter.

[0057] Screening of expression vectors

[0058] In order to investigate the effect of expression vector copy number on protein expression, plasmid vectors pP43NMK and pHT-01 with different copy numbers were used as expression vectors to express HLF. The results are shown in lanes 3 and 4 of Figure 1. It can be seen that the protein expression level of pHT-01 vector is higher than that of P43NMK vector.

[0059] Therefore, the present invention constructs a recombinant expression plasmid using pHT-01 as an expression vector and P21 as a promoter. As shown in Figure 2, the constructed human lactoferrin HLF expression cassette consists of the HLF gene and two parts, a 6×His tag. The Genbank accession number for HLF is AAA59511.1, and it has been optimized according to the codon preference of B. subtilis. Its nucleotide sequence and amino acid sequence are shown in SEQ ID NO. 1 and SEQ ID NO. 2, respectively. The nucleotide sequence of the promoter P21 is shown in SEQ ID NO. 3. The nucleotide sequence and amino acid sequence of the 6×His tag are shown in SEQ ID NO. 4 and SEQ ID NO. 5, respectively. This tag can be used to purify the recombinant protein using a nickel column.

[0060] In order to enhance the expression of HLF in B. subtilis, the expression vector used was the commercial plasmid pHT-01 vector, which is a stable protein expression vector. H HLF was expressed using the promoter P21, which is recognized by the gene factor and is not expressed in E. coli, ensuring the smooth construction of the recombinant expression plasmid. High and sustained expression was achieved in B. subtills. P21 and the synthesized genetic elements were ligated into the vector pHT-01 to create the vector pHT-P21-HLF. Transformation of this plasmid into the B. subtilis G601 strain yielded the engineered strain HLF1, which efficiently expresses HLF.

[0061] Example 2 Construction of HLF secretory expression plasmid

[0062] The SCORE method was used to screen for RBS-signal peptide combinations suitable for secretory expression of HLF. The specific plasmid construction method, primer design, validation primer design, and screening methods for this method were all described by Li et al. in A genetic toolkit for efficient production of secretory protein in Bacillus subtilis. Bioresource Technology, 2022. The principle of this method is to fuse the superfolder green fluorescent protein (sfGFP) to the HLF protein, and the fluorescence intensity in the fermentation supernatant is used to characterize the secretion of HLF. The signal peptide library screened consists of 173 signal peptides from the endogenous Sec secretion pathway of Bacillus subtilis and a library of 16 RBSs with different translation strengths, totaling 173 × 16 = 2768 combinations. The method operates as follows:

[0063] 1. The HLF protein sequence was connected to the screening plasmid to obtain the template plasmid pHT-P21-RBS-SP-HLF-sfGFP, which consists of the promoter P21, two Eco31Ⅰ restriction sites and the HLF-sfGFP fusion protein;

[0064] 2. Construct an RBS library. Using RBS (AAGGAGATATACC) as the initial RBS, degenerate primers RBS-F and RBS-R were used. Eco31Ⅰ restriction sites were added at both ends to obtain an RBS mixed library (MAGGMRGWATCAC). The library contains 16 RBSs with different transcription intensities.

[0065] 3. Construct a combinatorial signal peptide library. Download 173 signal peptides of the sec pathway of B. subtilis from the Signal Sequence Database. Design primers to add Eco31Ⅰ restriction sites at both ends of the signal peptide fragments. Amplify the fragments from the genome and mix them to obtain a signal peptide library.

[0066] 4. Use the Golden Gate method to connect the template plasmid pHT-P21-RBS-SP-HLF-sfGFP, RBS library and signal peptide library. The mixed system and PCR program are as follows:

[0067] Table 1 Golden gate connection system

[0068] Table 2 Reaction conditions

[0069] 5. Transform the constructed ligation vector into Escherichia coli for cloning to obtain a mixed plasmid, which was then transferred into Bacillus subtilis G601 and plated into a 96-well plate for fermentation verification. After 24 hours, centrifuge the plate at 4000 rpm for 5 minutes, aspirate the supernatant, and measure the fluorescence intensity of the supernatant.

[0070] 6. The fluorescence intensity of the supernatant ranged from 150 to 500. Six plasmids extracted from Bacillus subtilis with different fluorescence expression intensities were selected and sequenced to obtain six fusion protein expression plasmids with different RBS-signal peptide combinations. The nucleotide sequences of the RBS sequences and signal peptides are shown in Table 3. Two plasmids, 5 and 6, were selected, namely pHT-P21-RBS1-SP YycP -HLF and pHT-P21-RBS2-SP YncM -HLF is used for subsequent fermentation verification.

[0071] Table 3

[0072] 7. Remove the sfGFP gene sequence of the three plasmid vectors by PCR to obtain the HLF secretion expression vector pHT-P21-RBS1-SP YycP -HLF and pHT-P21-RBS2-SP YncM -HLF. Signal peptide SP YycP and SP YncM The nucleotide and amino acid sequences of RBS1 and RBS2 are shown in SEQ ID NOs. 6-7 and 8-9, respectively. The nucleotide sequences of RBS1 and RBS2 are shown in SEQ ID NOs. 10-11, respectively. After the above plasmids were transformed into B. subtilis G601 strain, engineered strains HLF2 and HLF3 that can efficiently express HLF were obtained.

[0073] Example 3 High-efficiency expression of HLF in recombinant strains

[0074] The engineered strain HLF1-3 obtained in Examples 1 and 2 was inoculated into a seed culture medium containing chloramphenicol (5 mg / L) and cultured with shaking at 37°C and 220 rpm overnight. A 4% inoculum (v / v) was then transferred to a fermentation medium containing chloramphenicol (5 mg / L) and cultured with shaking at 37°C and 220 rpm for 14-96 hours.

[0075] Example 4 Western blot analysis of HLF at different fermentation stages

[0076] Take samples of HLF1 at different fermentation stages, centrifuge at 8000×g for 2 min, discard the supernatant, wash the remaining bacteria twice with ultrapure water, and finally resuspend with ultrapure water. Dilute the bacterial resuspension to OD 600 The cells were disrupted using an ultrasonic disruptor with a pulse rate of approximately 5, using a 4-second operation cycle, a 2-second rest period, and a power setting of 38%. The disrupted liquid was sampled and mixed with loading buffer and then subjected to high-temperature treatment. HLF was then analyzed by Western blot. As shown in Figure 3, M: Marker, 1: 12-hour fermentation broth sample, 2: 24-hour fermentation broth sample, 3: 36-hour fermentation broth sample, 4: 48-hour fermentation broth sample, and 5: No-load control. The black dashed box indicates the protein band.

[0077] Example 5 Determination of protein yield of HLF

[0078] Using a human lactoferrin ELISA kit, the lactoferrin standard was graded diluted to concentrations of 0, 0.3125, 0.625, 1.25, 2.5, and 5 μg / L, respectively, and detected together with the sample. The absorbance was finally obtained as shown in Table 4, and a regression curve was drawn as shown in Figure 4. The fitting equation was y = 0.4346*x + 0.097, where x is the HLF protein concentration (μg / L) and y is the absorbance value.

[0079] Table 4 Absorbance of standard samples

[0080] 1 mL of each 24-h fermentation sample and a negative control were taken and serially diluted 100-fold. The samples were then tested in parallel. The results are shown in Table 5 and Figure 5 .

[0081] Table 5 HLF protein yield

[0082] Obviously, the above embodiments are merely examples for clarity of explanation and are not intended to limit the implementation methods. Those skilled in the art will appreciate that other variations or modifications can be made based on the above description. It is not necessary and impossible to enumerate all implementation methods here. Obvious variations or modifications arising therefrom remain within the scope of protection of the present invention.

Claims

1. A Bacillus subtilis for producing human lactoferrin, characterized in that: The Bacillus subtilis uses B. subtilis G601 as a starting strain and pHT-01 as an expression vector to heterologously express human lactoferrin regulated by a P21 promoter.

2. The Bacillus subtilis according to claim 1, characterized in that: The Bacillus subtilis also includes using an RBS sequence and a signal peptide to regulate the expression of human lactoferrin, wherein the nucleotide sequence of the RBS sequence is as shown in SEQ ID NO.10 or SEQ ID NO.11, and the signal peptide is selected from YycP or YncM.

3. The Bacillus subtilis according to claim 2, characterized in that: The amino acid sequence of the signal peptide YycP is shown in SEQ ID NO.

8.

4. The Bacillus subtilis according to claim 2, characterized in that: The amino acid sequence of the signal peptide YncM is shown in SEQ ID NO.

9.

5. The Bacillus subtilis according to claim 1, characterized in that: The B. subtilis G601 uses B. subtilis 168 as the starting bacterium, integrates the expression transcription factor comK-comS gene in the genome, reverses the mutation of the trpC gene and the gudB gene, and knocks out the extracellular protease serine protease gene aprE, the neutral protease gene nprE, the bacitracin gene bpr, the metalloprotease gene mpr and the neutral protease gene nprB.

6. The Bacillus subtilis according to claim 5, characterized in that: The back mutant trpC gene is obtained by mutating the tryptophan-deficient gene trpC2 in B. subtilis 168 into the wild-type gene trpC0 having a nucleotide sequence as shown in SEQ ID NO.

14.

7. The Bacillus subtilis according to claim 5, characterized in that: The back mutant gudB gene is to mutate the inactive gene gudB in B. subtilis 168 into an active gene gudB with a nucleotide sequence as shown in SEQ ID NO.15 + .

8. The Bacillus subtilis according to claim 1, characterized in that: The amino acid sequence of human lactoferrin is shown in SEQ ID NO.

2.

9. The Bacillus subtilis according to claim 1, characterized in that: The expression vector is also connected with a purification tag.

10. Use of the Bacillus subtilis producing human lactoferrin according to any one of claims 1 to 9 in producing lactoferrin.

11. A method for producing human lactoferrin, characterized in that: The fermentation production is carried out using the Bacillus subtilis described in any one of claims 1 to 9.

12. The method according to claim 11, characterized in that: After activating Bacillus subtilis, the bacillus subtilis is cultured in a seed culture medium to obtain a seed liquid, and then the seed liquid is inoculated into a fermentation culture medium for fermentation culture to prepare human lactoferrin.

13. The method according to claim 12, characterized in that: The seed culture medium is LB culture medium.

14. The method according to claim 12, characterized in that: The fermentation medium is TB medium.

15. The method according to claim 12, characterized in that: The seed solution was cultured in a fermentation medium at 35-37°C and 200-220 rpm.

Citation Information

Patent Citations

  • PLD (phospholipase D)-producing recombinant bacillus subtilis and application thereof

    CN109456929A

  • Bacillus subtilis with inactivated extracellular protease as well as construction method and application of bacillus subtilis

    CN113957028A

  • Dehydrated tetracycline-induced escherichia coli-bacillus subtilis universal inducible expression system

    CN114645062A

  • Recombinant Bacillus expressing lactoferrin and methodfor preparation thereof

    KR1020040108197A

  • Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms

    US5849881A